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Laboratoire Signalisation et Transports Ioniques Membranaires, University of Poitiers, CNRS, 1 rue Georges Bonnet, 86073 Poitiers, FranceThe past two decades have seen most research efforts targeted at
correcting the ion transport deﬁciency of cystic ﬁbrosis (CF), highlight-
ing the required promotion and development of new drugs to tackle CF
(Becq et al., 2011; Boyle and De Boeck, 2013; Riordan, 2008). The
polyexocrinopathy genetic disease CF is caused by one of the 2000 doc-
umented mutations in the cystic ﬁbrosis transmembrane conductance
regulator gene (CFTR, OMIM #602421) among them the deletion F508
(F508del-CFTR) is the most common and severe CF mutation (Boyle
and De Boeck, 2013; Riordan, 2008). F508del causes CFTR misfolding/
instability leading to defective protein biosynthesis, reduced plasma
membrane residence and altered channel gating (Riordan, 2008; Becq,
2010). Whereas it remains unclear whether current small molecules
targeting F508del-CFTRwill have therapeutic beneﬁt, thewind is never-
theless changing for CF patients who are still awaiting a curative treat-
ment. Indeed, new medications with orphan drug status are, for some,
rapidly progressing in clinical trials (Becq et al., 2011), among them
the F508del-CFTR corrector lumacaftor (VX-809) (Van Goor et al.,
2011). Acceleration of drug development has been clearly encouraged
by the recent successful marketing of Kalydeco®, the ﬁrst personalized
medication for CF patients directly targeting mutated CFTR proteins
(Ramsey et al., 2011).
The CFmutations can be classiﬁed into six classes (Welsh and Smith,
1993) helping research to being directed toward mutation-speciﬁc
therapeutic agents. The most severe cases of CF belong to classes I, II
and III, where little or no cAMP-dependent CFTR-mediated chloride
ion transport is observed in epithelia expressing CFTR mutants. Muta-
tions that have not been fully analyzed yet will be characterized as mu-
tations of unknown clinical signiﬁcance. Despite the fact that F508del-
CFTR is the main target for drug development in CF (Becq et al., 2011),
categorizing about 2000 individual mutations identiﬁed so far in pa-
tients worldwide would be a tough job while still remaining an im-
portant challenge. It is also necessary to understand whether the
mutation themselves can cause CF or not, or a CF-related disease
(e.g., congenital bilateral absence of the vas deferens or CBAVD, or
pancreatitis). For CF patients with a heterozygous genotype, it is
also important to understand whether carrying a CF-causing muta-
tion actually results in CF or not.
In theory, the goal for such a classiﬁcation is to predict the pheno-
type of a CF patient according to his/her genotype, but in practice this
critically depends on our ability to functionally characterize the mutant
CFTR. But, not all the CF mutations have been classiﬁed so far becauseDOI of original article: http://dx.doi.org/10.1016/j.ebiom.2014.12.005.
E-mail address: Frederic.becq@univ-poitiers.fr.
http://dx.doi.org/10.1016/j.ebiom.2015.01.013
2352-3964/© 2015 The Author. Published by Elsevier B.V. This is an open access article underthe function of CFTR remains unknown for many of them. Equally
important is the perspective, raising on the horizon, to propose a per-
sonalized medication according to the mutation(s) (Ikpa et al., 2014).
Although controversial, predicting drug-induced response is indeed an
attractive challenge that might well be added to (or even better re-
place) the therapeutic arsenal against the disease (Ikpa et al., 2014;
Balfour-Lynn, 2014).
However, if we aimed to functionally characterize most CFTR mu-
tants, then it is also important to determine how tomeasure CFTR activ-
ity with a rare mutation when testing corrector candidates and how to
take into consideration the genotype of the epithelial CF model cells.
In other words, if we want to personalize future treatments for CF pa-
tients, would it be necessary to systematically study most CF-related
mutations or group ofmutationsduringpre-clinical phase, and if the an-
swer is yes, then how? In this issue of EBioMedicine, a research group led
by Margarida Amaral (Awatade et al., 2015) described a method to
functionally characterize the activity of CFTR in human primary lung
cells by measuring the forskolin plus genistein-inducible equivalent
short-circuit current in perfused open-circuit Ussing chamber (forskolin
and genistein being pharmacological stimulators of CFTR). This study
provides important information. The authors evaluated and compared
the efﬁcacy of correctors lumacaftor (VX-809) and its analogue C18 on
epithelial cell preparations obtained from donors with different CF ge-
notypes — homozygous for F508del, A561E or heterozygous N1303K/
G542X, F508del/G542X, F508del/Y1092X. This strategy allowed them
to compare, using a robust functional assay, different CFTR mutations
in their native cell environment. Although they observed great variabil-
ity in VX-809 responses among patients, they were able to discriminate
CFTRmutants positively responding to the correctors such as A561E and
Y1092X and those that failed to respond, such as N1303K. They also
compared the efﬁcacy of the correctors and again found differences
for a given mutation. In principle, the protocol used by Awatade et al.
(2015). is simple and can be implemented in many research laborato-
ries worldwide, but it is not a common practice to use human bronchial
epithelial cells with different genotypes because suchmaterial is rare. It
is usually a long process to obtain enough patient samples and enough
epithelial cell quantities within the tissue sample to complete a study
and collaboration between transplantation and research centers are
generally complicated to set up. These results are thus telling us that
not only might it be important to use human primary epithelial cells
with various genotypes but it might equally be important to test several
correctors for each CFTR mutant due to different mechanisms of action.
Therefore, whereas the study of Awatade et al. (2015) conﬁrms the
feasibility of exploring how CFTR might work with different mutationsthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
101F. Becq / EBioMedicine 2 (2015) 100–101and with the best front-runner CF correctors, if the future for the
disease is to tailor an appropriate pharmaceutical product, then it
will require a great amount of effort to correlate drug effect with
speciﬁc CF mutations.
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